An Evidence-Based Multidisciplinary Approach Focused at Creating Algorithms for Targeted Therapy of BSIs, cUTIs, and cIAIs Caused by Enterobacterales in Critically Ill Adult Patients

References

• Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369(9):840–851. doi:10.1056/NEJMra120862323984731
   PubMed Web of Science ®Google Scholar
• Kaukonen K-M, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA. 2014;311(13):1308–1316. doi:10.1001/jama.2014.263724638143
   PubMed Web of Science ®Google Scholar
• Vincent J-L, Sakr Y, Singer M, et al. Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA. 2020;323(15):1478–1487. doi:10.1001/jama.2020.271732207816
   PubMed Web of Science ®Google Scholar
• Alberti C, Brun-Buisson C, Burchardi H, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med. 2002;28(2):108–121. doi:10.1007/s00134-001-1143-z11907653
   PubMed Web of Science ®Google Scholar
• MacVane SH. Antimicrobial resistance in the intensive care unit: a focus on gram-negative bacterial infections. J Intensive Care Med. 2017;32(1):25–37. doi:10.1177/088506661561989526772199
   PubMed Web of Science ®Google Scholar
• Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). Diagn Microbiol Infect Dis. 2014;78(4):443–448. doi:10.1016/j.diagmicrobio.2013.11.02524492025
   PubMed Web of Science ®Google Scholar
• Timsit J-F, Bassetti M, Cremer O, et al. Rationalizing antimicrobial therapy in the ICU: a narrative review. Intensive Care Med. 2019;45(2):172–189. doi:10.1007/s00134-019-05520-530659311
   PubMed Web of Science ®Google Scholar
• Detsis M, Karanika S, Mylonakis E. ICU acquisition rate, risk factors, and clinical significance of digestive tract colonization with extended-spectrum beta-lactamase-producing enterobacteriaceae: a systematic review and meta-analysis. Crit Care Med. 2017;45(4):705–714. doi:10.1097/CCM.000000000000225328157141
   PubMed Web of Science ®Google Scholar
• Thabit AK, Crandon JL, Nicolau DP. Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials. Expert Opin Pharmacother. 2015;16(2):159–177. doi:10.1517/14656566.2015.99338125496207
   PubMed Web of Science ®Google Scholar
• Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009;136(5):1237–1248. doi:10.1378/chest.09-008719696123
   PubMed Web of Science ®Google Scholar
• Ulldemolins M, Nuvials X, Palomar M, Masclans JR, Rello J. Appropriateness is critical. Crit Care Clin. 2011;27(1):35–51. doi:10.1016/j.ccc.2010.09.00721144985
   PubMed Web of Science ®Google Scholar
• Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–377. doi:10.1007/s00134-017-4683-628101605
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P. Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter? Crit Care. 2009;13(3):214. doi:10.1186/cc777419519961
   PubMed Web of Science ®Google Scholar
• Viale P, Tedeschi S, Scudeller L, et al. Infectious Diseases Team for the Early Management of Severe Sepsis and Septic Shock in the Emergency Department. Clin Infect Dis. 2017;65(8):1253–1259. doi:10.1093/cid/cix548
   PubMed Web of Science ®Google Scholar
• Gatti M, Gasparini LE, Laratta M, et al. Intensive multidisciplinary management in critical care patients affected by severe necrotizing soft tissue infections: a cooperative method to improve the efficacy of treatment. Eur J Clin Microbiol Infect Dis. 2019;38(6):1153–1162. doi:10.1007/s10096-019-03521-230840159
   PubMed Web of Science ®Google Scholar
• Chen M, Zhang M, Huang P, et al. Novel β-lactam/β-lactamase inhibitors versus alternative antibiotics for the treatment of complicated intra-abdominal infection and complicated urinary tract infection: a meta-analysis of randomized controlled trials. Expert Rev Anti Infect Ther. 2018;16(2):111–120. doi:10.1080/14787210.2018.142991229343141
   PubMed Web of Science ®Google Scholar
• Gudiol C, Cuervo G, Carratalà J. Optimizing therapy of bloodstream infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae. Curr Opin Crit Care. 2019;25(5):438–448. doi:10.1097/MCC.000000000000064631369411
   PubMed Web of Science ®Google Scholar
• Delgado-Valverde M, Torres E, Valiente-Mendez A, et al. Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project. J Antimicrob Chemother. 2016;71(2):521–530. doi:10.1093/jac/dkv36226538507
   PubMed Web of Science ®Google Scholar
• Murad MH, Asi N, Alsawas M, Alahdab F. New evidence pyramid. Evid Based Med. 2016;21(4):125–127. doi:10.1136/ebmed-2016-11040127339128
   PubMedGoogle Scholar
• Eckmann C, Dryden M, Montravers P, Kozlov R, Sganga G. Antimicrobial treatment of “complicated” intra-abdominal infections and the new IDSA guidelines? a commentary and an alternative European approach according to clinical definitions. Eur J Med Res. 2011;16(3):115–126. doi:10.1186/2047-783x-16-3-11521486724
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(2):133–164. doi:10.1086/64955420034345
   PubMed Web of Science ®Google Scholar
• Walker AP, Nichols RL, Wilson RF, et al. Efficacy of a beta-lactamase inhibitor combination for serious intraabdominal infections. Ann Surg. 1993;217(2):115–121. doi:10.1097/00000658-199302000-000048439209
   PubMed Web of Science ®Google Scholar
• McKinnon PS, Neuhauser MM. Efficacy and cost of ampicillin-sulbactam and ticarcillin-clavulanate in the treatment of hospitalized patients with bacterial infections. Pharmacotherapy. 1999;19(6):724–733. doi:10.1592/phco.19.9.724.3153710391418
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Lode H, Grassi C. Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gram-negative infections. Antibiotic Study Group. Clin Infect Dis. 1995;20(5):1217–1228. doi:10.1093/clinids/20.5.12177620002
   PubMed Web of Science ®Google Scholar
• Tomera KM, Burdmann EA, Reyna OGP, et al. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. Antimicrob Agents Chemother. 2002;46(9):2895–2900. doi:10.1128/aac.46.9.2895-2900.200212183244
   PubMed Web of Science ®Google Scholar
• Jimenez-Cruz F, Jasovich A, Cajigas J, et al. A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. Urology. 2002;60(1):16–22. doi:10.1016/s0090-4295(02)01664-312100914
   PubMed Web of Science ®Google Scholar
• Wells WG, Woods GL, Jiang Q, Gesser RM. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. J Antimicrob Chemother. 2004;53(Suppl 2):ii67–74. doi:10.1093/jac/dkh20815150185
   PubMed Web of Science ®Google Scholar
• Park DW, Peck KR, Chung MH, et al. Comparison of ertapenem and ceftriaxone therapy for acute pyelonephritis and other complicated urinary tract infections in Korean adults: a randomized, double-blind, multicenter trial. J Korean Med Sci. 2012;27(5):476–483. doi:10.3346/jkms.2012.27.5.47622563210
   PubMed Web of Science ®Google Scholar
• Paterson DL, Henderson A, Harris PNA. Current evidence for therapy of ceftriaxone-resistant Gram-negative bacteremia. Curr Opin Infect Dis. 2020;33(1):78–85. doi:10.1097/QCO.000000000000062331834029
   PubMed Web of Science ®Google Scholar
• Papadimitriou-Olivgeris M, Bartzavali C, Lambropoulou A, et al. Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam. J Antimicrob Chemother. 2019;74(7):2051–2054. doi:10.1093/jac/dkz12531002313
   PubMed Web of Science ®Google Scholar
• Harris PNA, Tambyah PA, Lye DC, et al. Effect of Piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA. 2018;320(10):984–994. doi:10.1001/jama.2018.1216330208454
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Kahlmeter G. Antibiotics for Ceftriaxone-resistant gram-negative bacterial bloodstream infections. JAMA. 2019;321(6):612–613. doi:10.1001/jama.2018.19345
   Web of Science ®Google Scholar
• Livermore DM, Day M, Cleary P, et al. OXA-1 β-lactamase and non-susceptibility to penicillin/β-lactamase inhibitor combinations among ESBL-producing Escherichia coli. J Antimicrob Chemother. 2019;74(2):326–333. doi:10.1093/jac/dky45330388219
   PubMed Web of Science ®Google Scholar
• Sfeir MM, Askin G, Christos P. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis. Int J Antimicrob Agents. 2018;52(5):554–570. doi:10.1016/j.ijantimicag.2018.07.02130081138
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Navarro MD, Retamar P, Picón E, Á P. Extended-Spectrum Beta-Lactamases–Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria Group. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012;54(2):167–174. doi:10.1093/cid/cir79022057701
   PubMed Web of Science ®Google Scholar
• Kang C-I, Park SY, Chung DR, Peck KR, Song J-H. Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J Infect. 2012;64(5):533–534. doi:10.1016/j.jinf.2012.01.00822274414
   PubMed Web of Science ®Google Scholar
• Harris PNA, Yin M, Jureen R, et al. Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae. Antimicrob Resist Infect Control. 2015;4:14. doi:10.1186/s13756-015-0055-625932324
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Gutiérrez B, Pérez-Galera S, Salamanca E, et al. A multinational, preregistered cohort study of β-Lactam/β-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase-producing enterobacteriaceae. Antimicrob Agents Chemother. 2016;60(7):4159–4169. doi:10.1128/AAC.00365-1627139473
   PubMed Web of Science ®Google Scholar
• Ng TM, Khong WX, Harris PNA, et al. Empiric Piperacillin-tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing enterobacteriaceae. PLoS One. 2016;11(4):e0153696. doi:10.1371/journal.pone.015369627104951
   PubMed Web of Science ®Google Scholar
• Gudiol C, Royo-Cebrecos C, Abdala E, et al. Efficacy of β-Lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum-β-lactamase-producing enterobacteriaceae in hematological patients with neutropenia. Antimicrob Agents Chemother. 2017;61:8. doi:10.1128/AAC.00164-17
   Web of Science ®Google Scholar
• Yoon YK, Kim JH, Sohn JW, Yang KS, Kim MJ. Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli. Int J Antimicrob Agents. 2017;49(4):410–415. doi:10.1016/j.ijantimicag.2016.12.01728263710
   PubMed Web of Science ®Google Scholar
• Ko J-H, Lee NR, Joo E-J, et al. Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study. Eur J Clin Microbiol Infect Dis. 2018;37(2):305–311. doi:10.1007/s10096-017-3133-229177611
   PubMed Web of Science ®Google Scholar
• Benanti GE, Brown ART, Shigle TL, et al. Carbapenem versus cefepime or piperacillin-tazobactam for empiric treatment of bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli in patients with hematologic malignancy. Antimicrob Agents Chemother. 2019;63:2. doi:10.1128/AAC.01813-18
   Web of Science ®Google Scholar
• John R, Colley P, Nguyen HL, Berhe M. Outcomes analysis in patients with extended-spectrum beta-lactamase bacteremia empirically treated with piperacillin/tazobactam versus carbapenems. Proc (Bayl Univ Med Cent). 2019;32(2):187–191. doi:10.1080/08998280.2019.158246631191124
   PubMedGoogle Scholar
• Nasir N, Ahmed S, Razi S, Awan S, Mahmood SF. Risk factors for mortality of patients with ceftriaxone resistant E. coli bacteremia receiving carbapenem versus beta lactam/beta lactamase inhibitor therapy. BMC Res Notes. 2019;12(1):611. doi:10.1186/s13104-019-4648-731547853
   PubMed Web of Science ®Google Scholar
• Sharara SL, Amoah J, Pana ZD, Simner PJ, Cosgrove SE, Tamma PD. Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by Extended-Spectrum β-Lactamase-Producing Organisms? Clin Infect Dis. 2020;71(8):e331–e337. doi:10.1093/cid/ciz120531859352
   PubMed Web of Science ®Google Scholar
• Seo YB, Lee J, Kim YK, et al. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli. BMC Infect Dis. 2017;17(1):404. doi:10.1186/s12879-017-2502-x28592240
   PubMed Web of Science ®Google Scholar
• Tamma PD, Han JH, Rock C, et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia. Clin Infect Dis. 2015;60(9):1319–1325. doi:10.1093/cid/civ00325586681
   PubMed Web of Science ®Google Scholar
• Ofer-Friedman H, Shefler C, Sharma S, et al. Carbapenems versus piperacillin-tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum beta-lactamase-producing enterobacteriaceae. Infect Control Hosp Epidemiol. 2015;36(8):981–985. doi:10.1017/ice.2015.10125990361
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Voulgaris GL, Maliaros A, Samonis G, Falagas ME. Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. Lancet Infect Dis. 2018;18(1):108–120. doi:10.1016/S1473-3099(17)30615-129102324
   PubMed Web of Science ®Google Scholar
• Thabit AK, Hobbs ALV, Guzman OE, Shea KM. the pharmacodynamics of prolonged infusion β-lactams for the treatment of pseudomonas aeruginosa infections: a systematic review. Clin Ther. 2019;41(11):2397–2415.e8. doi:10.1016/j.clinthera.2019.09.01031679822
   PubMed Web of Science ®Google Scholar
• Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, Phase 3 trial (ASPECT-cUTI). Lancet. 2015;385(9981):1949–1956. doi:10.1016/S0140-6736(14)62220-025931244
   PubMed Web of Science ®Google Scholar
• Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/Tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015;60(10):1462–1471. doi:10.1093/cid/civ09725670823
   PubMed Web of Science ®Google Scholar
• Wagenlehner FM, Sobel JD, Newell P, et al. Ceftazidime-avibactam Versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a Phase 3 randomized trial program. Clin Infect Dis. 2016;63(6):754–762. doi:10.1093/cid/ciw37827313268
   PubMed Web of Science ®Google Scholar
• Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis. 2016;62(11):1380–1389. doi:10.1093/cid/ciw13326962078
   PubMed Web of Science ®Google Scholar
• Qin X, Tran BG, Kim MJ, et al. A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia. Int J Antimicrob Agents. 2017;49(5):579–588. doi:10.1016/j.ijantimicag.2017.01.01028363526
   PubMed Web of Science ®Google Scholar
• Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16(6):661–673. doi:10.1016/S1473-3099(16)30004-427107460
   PubMed Web of Science ®Google Scholar
• Meini S, Tascini C, Cei M, Sozio E, Rossolini GM. AmpC β-lactamase-producing Enterobacterales: what a clinician should know. Infection. 2019;47(3):363–375. doi:10.1007/s15010-019-01291-930840201
   PubMed Web of Science ®Google Scholar
• Harris PNA, Wei JY, Shen AW, et al. Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis. J Antimicrob Chemother. 2016;71(2):296–306. doi:10.1093/jac/dkv34626542304
   PubMed Web of Science ®Google Scholar
• Blanchette LM, Kuti JL, Nicolau DP, Nailor MD. Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing Enterobacteriaceae. Scand J Infect Dis. 2014;46(11):803–808. doi:10.3109/00365548.2014.95426225262922
   PubMed Web of Science ®Google Scholar
• Tamma PD, Girdwood SCT, Gopaul R, et al. The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae. Clin Infect Dis. 2013;57(6):781–788. doi:10.1093/cid/cit39523759352
   PubMed Web of Science ®Google Scholar
• Siedner MJ, Galar A, Guzmán-Suarez BB, et al. Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia. Clin Infect Dis. 2014;58(11):1554–1563. doi:10.1093/cid/ciu18224647022
   PubMed Web of Science ®Google Scholar
• Hilty M, Sendi P, Seiffert SN, et al. Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy? Int J Antimicrob Agents. 2013;41(3):236–249. doi:10.1016/j.ijantimicag.2012.10.02223313399
   PubMed Web of Science ®Google Scholar
• Tan SH, Ng TM, Chew KL, et al. Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems vs. non-carbapenems. Int J Antimicrob Agents. 2020;55(2):105860. doi:10.1016/j.ijantimicag.2019.10586031841674
   PubMed Web of Science ®Google Scholar
• Lee N-Y, Lee -C-C, Li C-W, et al. Cefepime therapy for monomicrobial enterobacter cloacae bacteremia: unfavorable outcomes in patients infected by cefepime-susceptible dose-dependent isolates. Antimicrob Agents Chemother. 2015;59(12):7558–7563. doi:10.1128/AAC.01477-1526416853
   PubMed Web of Science ®Google Scholar
• Cheng L, Nelson BC, Mehta M, et al. Piperacillin-tazobactam versus other antibacterial agents for treatment of bloodstream infections due to AmpC β-lactamase-producing enterobacteriaceae. Antimicrob Agents Chemother. 2017;61:6. doi:10.1128/AAC.00276-17
   Web of Science ®Google Scholar
• van Duin D, Lok JJ, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant enterobacteriaceae. Clin Infect Dis. 2018;66(2):163–171. doi:10.1093/cid/cix78329020404
   PubMed Web of Science ®Google Scholar
• Castón JJ, Lacort-Peralta I, Martín-Dávila P, et al. Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients. Int J Infect Dis. 2017;59:118–123. doi:10.1016/j.ijid.2017.03.02128392315
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, Corona A, et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Infect Dis. 2019;68(3):355–364. doi:10.1093/cid/ciy49229893802
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-Avibactam is superior to other treatment regimens against carbapenem-resistant klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017;61:8. doi:10.1128/AAC.00883-17
   Web of Science ®Google Scholar
• Temkin E, Torre-Cisneros J, Beovic B, et al. Ceftazidime-Avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother. 2017;61:2. doi:10.1128/AAC.01964-16
   Web of Science ®Google Scholar
• King M, Heil E, Kuriakose S, et al. Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant enterobacteriaceae infections. Antimicrob Agents Chemother. 2017;61:7. doi:10.1128/AAC.00449-17
   Web of Science ®Google Scholar
• Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae infections. Clin Infect Dis. 2016;63(12):1615–1618. doi:10.1093/cid/ciw63627624958
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Chen L, Press EG, Kreiswirth BN, Clancy CJ. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant enterobacteriaceae infections. Antimicrob Agents Chemother. 2018;62:5. doi:10.1128/AAC.02497-17
   Web of Science ®Google Scholar
• Tumbarello M, Raffaelli F, Giannella M, et al. Ceftazidime-avibactam use for KPC-Kp infections: a retrospective observational multicenter study. Clin Infect Dis. 2021. doi:10.1093/cid/ciab176
   PubMed Web of Science ®Google Scholar
• Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, New LL. β-Lactam-β-Lactamase Inhibitor Combinations. Clin Microbiol Rev. 2020;34:1. doi:10.1128/CMR.00115-20
   Web of Science ®Google Scholar
• Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018;7(4):439–455. doi:10.1007/s40121-018-0214-130270406
   PubMed Web of Science ®Google Scholar
• Ackley R, Roshdy D, Meredith J, et al. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections. Antimicrob Agents Chemother. 2020;64:5. doi:10.1128/AAC.02313-19
   Web of Science ®Google Scholar
• Alosaimy S, Jorgensen SCJ, Lagnf AM, et al. Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious gram-negative bacterial infections. Open Forum Infect Dis. 2020;7(3):ofaa051. doi:10.1093/ofid/ofaa05132161775
   PubMed Web of Science ®Google Scholar
• Shields RK, McCreary EK, Marini RV, et al. Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections. Clin Infect Dis. 2020;71(3):667–671. doi:10.1093/cid/ciz113131738396
   PubMed Web of Science ®Google Scholar
• Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1: a Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections. Clin Infect Dis. 2020;70(9):1799–1808. doi:10.1093/cid/ciz53031400759
   PubMed Web of Science ®Google Scholar
• Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226–240. doi:10.1016/S1473-3099(20)30796-933058795
   PubMed Web of Science ®Google Scholar
• Stewart A, Harris P, Henderson A, Paterson D. Treatment of Infections by OXA-48-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2018;62:11. doi:10.1128/AAC.01195-18
   Web of Science ®Google Scholar
• Alraddadi BM, Saeedi M, Qutub M, Alshukairi A, Hassanien A, Wali G. Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae. BMC Infect Dis. 2019;19(1):772. doi:10.1186/s12879-019-4409-131484510
   PubMed Web of Science ®Google Scholar
• De la Calle C, Rodríguez O, Morata L, et al. Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam. Int J Antimicrob Agents. 2019;53(4):520–524. doi:10.1016/j.ijantimicag.2018.11.01530471403
   PubMed Web of Science ®Google Scholar
• Sousa A, Pérez-Rodríguez MT, Soto A, et al. Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2018;73(11):3170–3175. doi:10.1093/jac/dky29530099490
   PubMed Web of Science ®Google Scholar
• Contreras DA, Fitzwater SP, Nanayakkara DD, et al. Coinfections of Two Strains of NDM-1- and OXA-232-Coproducing Klebsiella pneumoniae in a Kidney Transplant Patient. Antimicrob Agents Chemother. 2020;64:4. doi:10.1128/AAC.00948-19
   Web of Science ®Google Scholar
• Dobias J, Dénervaud-Tendon V, Poirel L, Nordmann P. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens. Eur J Clin Microbiol Infect Dis. 2017;36(12):2319–2327. doi:10.1007/s10096-017-3063-z28748397
   PubMed Web of Science ®Google Scholar
• Kazmierczak KM, Tsuji M, Wise MG, et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study). Int J Antimicrob Agents. 2019;53(2):177–184. doi:10.1016/j.ijantimicag.2018.10.00730395986
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Abdelhamed AM, Good CE, et al. ARGONAUT-I: activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases. Antimicrob Agents Chemother. 2019;63:1. doi:10.1128/AAC.01801-18
   Web of Science ®Google Scholar
• Delgado-Valverde M, Conejo MDC, Serrano L, Fernández-Cuenca F, Pascual Á. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia. J Antimicrob Chemother. 2020;75(7):1840–1849. doi:10.1093/jac/dkaa11732277821
   PubMed Web of Science ®Google Scholar
• Boyd SE, Livermore DM, Hooper DC, Hope WW. Metallo-β-Lactamases: structure, function, epidemiology, treatment options, and the development pipeline. Antimicrob Agents Chemother. 2020;64:10. doi:10.1128/AAC.00397-20
   Web of Science ®Google Scholar
• Falcone M, Daikos GL, Tiseo G, et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL- producing Enterobacterales. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa586
   Web of Science ®Google Scholar
• Shaw E, Rombauts A, Tubau F, et al. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection. J Antimicrob Chemother. 2018;73(4):1104–1106. doi:10.1093/jac/dkx49629272413
   PubMed Web of Science ®Google Scholar
• Benchetrit L, Mathy V, Armand-Lefevre L, Bouadma L, Timsit J-F. Successful treatment of septic shock due to NDM-1-producing Klebsiella pneumoniae using ceftazidime/avibactam combined with aztreonam in solid organ transplant recipients: report of two cases. Int J Antimicrob Agents. 2020;55(1):105842. doi:10.1016/j.ijantimicag.2019.10.02331704216
   PubMed Web of Science ®Google Scholar
• Shah PJ, Tran T, Emelogu F, Tariq F. Aztreonam, Ceftazidime/Avibactam, and Colistin Combination for the Management of Carbapenemase-Producing Klebsiella Pneumoniae Bacteremia: a Case Report. J Pharm Pract. 2019;897190019882262. doi:10.1177/0897190019882262
   Web of Science ®Google Scholar
• Hobson CA, Bonacorsi S, Fahd M, et al. Successful Treatment of Bacteremia Due to NDM-1-Producing Morganella morganii with Aztreonam and Ceftazidime-Avibactam Combination in a Pediatric Patient with Hematologic Malignancy. Antimicrob Agents Chemother. 2019;63:2. doi:10.1128/AAC.02463-18
   Web of Science ®Google Scholar
• Sieswerda E, van den Brand M, van den Berg RB, et al. Successful rescue treatment of sepsis due to a pandrug-resistant, NDM-producing Klebsiella pneumoniae using aztreonam powder for nebulizer solution as intravenous therapy in combination with ceftazidime/avibactam. J Antimicrob Chemother. 2020;75(3):773–775. doi:10.1093/jac/dkz49531789378
   PubMed Web of Science ®Google Scholar
• Yasmin M, Fouts DE, Jacobs MR, et al. Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1. Clin Infect Dis. 2020;71(4):1095–1098. doi:10.1093/cid/ciz115531802119
   PubMed Web of Science ®Google Scholar
• Bocanegra-Ibarias P, Camacho-Ortiz A, Garza-González E, Flores-Treviño S, Kim H, Perez-Alba E. Aztreonam plus ceftazidime-avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: last resort therapy? J Glob Antimicrob Resist. 2020;23:417–419. doi:10.1016/j.jgar.2020.10.01933212285
   PubMed Web of Science ®Google Scholar
• Cairns KA, Hall V, Martin GE, et al. Treatment of invasive IMP-4 Enterobacter cloacae infection in transplant recipients using ceftazidime/avibactam with aztreonam: a case series and literature review. Transpl Infect Dis. 2020. doi:10.1111/tid.13510
   Web of Science ®Google Scholar
• Mushtaq S, Sadouki Z, Vickers A, Livermore DM, Woodford N. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria. Antimicrob Agents Chemother. 2020;64:12. doi:10.1128/AAC.01582-20
   Web of Science ®Google Scholar
• Seija V, Medina Presentado JC, Bado I, et al. Sepsis caused by New Delhi metallo-β-lactamase (blaNDM-1) and qnrD-producing Morganella morganii, treated successfully with fosfomycin and meropenem: case report and literature review. Int J Infect Dis. 2015;30:20–26. doi:10.1016/j.ijid.2014.09.01025447717
   PubMed Web of Science ®Google Scholar
• Erturk Sengel B, Altinkanat Gelmez G, Soyletir G, Korten V. In vitro synergistic activity of fosfomycin in combination with meropenem, amikacin and colistin against OXA-48 and/or NDM-producing Klebsiella pneumoniae. J Chemother. 2020;32(5):237–243. doi:10.1080/1120009X.2020.174550132228228
   PubMed Web of Science ®Google Scholar
• Tamma PD, The R-BJ. Use of noncarbapenem β-lactams for the treatment of extended-spectrum β-lactamase infections. Clin Infect Dis. 2017;64(7):972–980. doi:10.1093/cid/cix03428362938
   PubMed Web of Science ®Google Scholar
• Collins VL, Marchaim D, Pogue JM, et al. Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2012;56(4):2173–2177. doi:10.1128/AAC.05913-1122290982
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Gutiérrez B, Bonomo RA, Carmeli Y, et al. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. J Antimicrob Chemother. 2016;71(6):1672–1680. doi:10.1093/jac/dkv50226907184
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Carbapenem-Sparing GH. Strategies for ESBL producers: when and how. Antibiotics (Basel). 2020;9:2. doi:10.3390/antibiotics9020061
   Web of Science ®Google Scholar
• Pilmis B, Petitjean G, Lesprit P, et al. Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2019;38(8):1457–1461. doi:10.1007/s10096-019-03573-431073653
   PubMed Web of Science ®Google Scholar
• Meini S, Viaggi B, Tascini C. Mono vs. combo regimens with novel beta-lactam/beta-lactamase inhibitor combinations for the treatment of infections due to carbapenemase-producing Enterobacterales: insights from the literature. Infection. 2021. doi:10.1007/s15010-021-01577-x
   Web of Science ®Google Scholar
• Onorato L, Di Caprio G, Signoriello S, Coppola N. Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: a meta-analysis. Int J Antimicrob Agents. 2019;54(6):735–740. doi:10.1016/j.ijantimicag.2019.08.02531479738
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Ciacco E, Girmenia C, et al. Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: a Review of the Emerging Data. Infect Drug Resist. 2020;13:4697–4711. doi:10.2147/IDR.S20530933402840
   PubMed Web of Science ®Google Scholar
• Kohira N, Hackel MA, Ishioka Y, et al. Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014). J Glob Antimicrob Resist. 2020;22:738–741. doi:10.1016/j.jgar.2020.07.00932702396
   PubMed Web of Science ®Google Scholar
• Gatti M, Pea F. Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors. Expert Rev Clin Pharmacol. 2021. doi:10.1080/17512433.2021.1901574
   PubMed Web of Science ®Google Scholar